Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;43(5):898-901.
doi: 10.1007/s10875-023-01454-2. Epub 2023 Mar 7.

STAT1 Gain-of-Function and Hidradenitis Suppurativa Successfully Managed with Baricitinib

Peter Olbrich  1   2 , José Ivorra Cortés  3 , Olaf Neth  4 , Pilar Blanco-Lobo  1 ; IEI, Dermatology and Rheumatology Research group
Collaborators, Affiliations

STAT1 Gain-of-Function and Hidradenitis Suppurativa Successfully Managed with Baricitinib

Peter Olbrich et al. J Clin Immunol. 2023 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Summary of the clinical course of the patient and laboratory results. A Clinical symptoms and treatments prescribed. 1Antibiotics: metronidazole, amoxicillin/clavulanic acid, and minocycline; 2ciprofloxacin and cloxacillin; 3Infliximab 5 mg/kg every 8 weeks; 4Adalimumab 80 mg every 2 weeks. B Clinical features of the patient with oral thrush (top) and hidradenitis lesions (bottom). C IFN-γ-dependent STAT1 activation in patient and healthy control’s CD14 + monocytes in the presence of different Ruxolitinib or Baricitinib concentrations. D IFN-γ-dependent STAT1 activation in patient and healthy control’s CD14 + monocytes at different time points: before Baricitinib initiation, after 2.5 and 4 months, and during Baricitinib discontinuation because of pregnancy. Geometric mean fluorescence intensity (gMFI) of total STAT1 (left) and pSTAT1 (right). The same age and sex matched healthy control was used for all time points
See this image and copyright information in PMC

References

    1. Deya-Martinez A, Riviere JG, Roxo-Junior P, Ramakers J, Bloomfield M, Guisado Hernandez P, et al. Impact of JAK inhibitors in pediatric patients with STAT1 gain of function (GOF) mutations-10 children and review of the literature. J Clin Immunol. 2022;42(5):1071–1082. doi: 10.1007/s10875-022-01257-x. - DOI - PMC - PubMed
    1. Sabat R, Jemec GBE, Matusiak L, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18. doi: 10.1038/s41572-020-0149-1. - DOI - PubMed
    1. Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, et al. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol. 2014;54(12):1354–1361. doi: 10.1002/jcph.354. - DOI - PubMed
    1. Rumberger BE, Boarder EL, Owens SL, Howell MD. Transcriptomic analysis of hidradenitis suppurativa skin suggests roles for multiple inflammatory pathways in disease pathogenesis. Inflamm Res. 2020;69(10):967–973. doi: 10.1007/s00011-020-01381-7. - DOI - PubMed
    1. Guisado Hernandez P, Blanco Lobo P, Villaoslada I, de Felipe B, Lucena JM, Martin Gutierrez G, et al. SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance? J Clin Immunol. 2021;41(7):1502–1506. doi: 10.1007/s10875-021-01081-9. - DOI - PMC - PubMed

Publication types

MeSH terms